GC Pharm to develop next-gen premium vaccine in U.S.

GC Pharm will develop a next-generation premium vaccine in the U.S.

GC Pharm(CEO Eun-Cheol Huh) announced on the 21^st that the company would found a new company called ‘CUREVO’ in Seattle, Washington and start to develop the next-generation vaccine.

The newly founded CUREVO is planning to conduct clinical trials in the U.S. for ‘CRV-101(GC Pharm’s project name: MG1120),’ a shingles vaccine jo...